Dihydroergotamine mesylate
Based on 6 publication(s) in Google Scholar
Dihydroergotamine mesylate is a blood-brain barrier-permeable semi-synthetic ergot alkaloid, acting as a full agonist of 5-HT1B/1D receptors (Ki values of 0.3 nM and 2.5 nM, respectively; functional IC50 values of 2 nM and 2.2 nM, respectively). Dihydroergotamine mesylate inhibits Forskolin (HY-15371)-stimulated cAMP accumulation, possesses α-adrenergic receptor antagonistic activity and weak dopaminergic agonistic activity. It mediates intracranial cerebrovascular contraction, inhibits the release of neuropeptides such as CGRP/substance P, and suppresses neurogenic inflammation by activating 5-HT1B/1D receptors in the trigeminovascular system. Dihydroergotamine mesylate binds to the catalytic site of Trypanosoma cruzi trypanothione reductase and exhibits trypanocidal activity in vitro. Dihydroergotamine mesylate can be used in studies related to migraine and trypanosome infections.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 6190-39-2
- Formula: C34H41N5O8S
- Molecular Weight:679.78
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dihydroergotamine mesylate
More
Customer Validation & Images
-
Cell Imaging/Staining
-
WB
-
WB
-
IP
-
Bio/Physico-chemical Assay
All Adrenergic Receptor Isoforms
MoreAll 5-HT Receptor Isoforms
MoreAll Dopamine Receptor Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
α adrenergic receptor |
human 5-HT1B Receptor 0.3 nM (Ki) |
human 5-HT1D Receptor 2.5 nM (Ki) |
Dihydroergotamine mesylate binds with high affinity to human 5-HT1B receptors in butyrate-treated HEK293 cells (Ki = 0.3 nM), human 5-HT1B receptors in mIFNβ-induced L929sA cells (Ki = 0.5 nM), and human 5-HT1D receptors in butyrate-treated C6 glioma cells (Ki = 0.7 nM)[1].
Dihydroergotamine (20 min) mesylate fully inhibits Forskolin (HY-15371)-stimulated cAMP accumulation in L929sA and HEK 293 cells expressing human 5-HT1B receptors, with IC50 values of 0.4 nM and 2.0 nM, respectively[1].
Dihydroergotamine (20 min) mesylate completely inhibits Forskolin-stimulated cyclic AMP accumulation in mIFNβ-induced L929sA cells expressing human 5-HT1B receptors, with an IC50 of 0.4 nM[1].
Dihydroergotamine (20 min) mesylate completely inhibits Forskolin (IC50 = 2.2 nM)- and isoproterenol-stimulated cyclic AMP accumulation in C6 glioma cells expressing the human 5-HT1D receptor[1].
Dihydroergotamine (0.01-1 μM; 24 h) mesylate protects Neuro-2a neuronal cells against oxygen-glucose deprivation-induced injury, with a significant increase in cell viability observed[3].
Dihydroergotamine mesylate binds to the catalytic site of Trypanosoma cruzi trypanothione reductase, with a docking score of -9.536 kcal/mol[4].
Dihydroergotamine (6.25-100 μg/mL; 24 h) mesylate exhibits an LC50 of 28.1 μM against the trypomastigote form of Trypanosoma cruzi strain NINOA and an LC50 of 57 μM against strain INC-5 in vitro, showing superior trypanocidal activity compared with reference trypanocidal drugs[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neuro-2a neuron cell line
-
Concentration:0.01 μM, 0.1 μM, 1 μM
-
Incubation Time:24 h
-
Result:Exerted no significant effect on the viability of untreated Neuro-2a cells.
Significantly increased Neuro-2a cell viability compared to the OGD-only group at 0.1 μM and 1 μM following OGD-induced injury.
Dihydroergotamine (10 mg/kg/day; i.p.; daily; 14 days) mesylate improves survival, neurological function, and reduces brain injury in MCAO mice by inhibiting pro-inflammatory cytokine production and promoting microglial/macrophage polarization toward the neuroprotective M2 phenotype[3].
Dihydroergotamine (100 mg/kg; single dose) mesylate reduces blood parasite survival to 62.44% at 8 hours post-administration in a short-term murine model of acute Chagas disease, with less efficacy than benznidazole[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 2-month-old, 22-25 g, middle cerebral artery occlusion induced via intraluminal filament method)[3]
-
Dosage:10 mg/kg/day
-
Administration:i.p.; daily; 14 days
-
Result:Improved 14-day survival rates in MCAO mice.
Reduced contact time and removal time in the adhesive removal test.
Improved motor function scores in the beam walking test compared to untreated MCAO mice.
Reduced cerebral infarct volume from ~50% to ~30% of contralateral hemisphere volume 3 days after MCAO.
Reduced brain tissue loss from ~16% to ~7% of contralateral hemisphere volume 14 days after MCAO.
Decreased ischemic hemisphere levels of IL-1β from ~0.005 pg/μg to ~0.003 pg/μg.
Decreased ischemic hemisphere levels of TNF-α from ~0.015 pg/μg to ~0.008 pg/μg.
Reduced the ratio of TNF-α/NeuN and IL-1β/NeuN positive neurons.
Decreased the relative level of M1 microglial/macrophage marker CD16 from ~3 to ~1.
Increased the relative level of M2 marker CD206 from ~0.7 to ~2.3 compared to untreated MCAO mice.
-
Animal Model:CD1 mice (female, 30-40 g, inoculated intraperitoneally with 1×105 Trypanosoma cruzi NINOA strain trypomastigotes/mL)[4]
-
Dosage:100 mg/kg
-
Administration:single dose
-
Result:Reduced blood parasite survival to 62.44% at 8 hours post-treatment.
Chemical Information
-
CAS No. 6190-39-2
-
Appearance Solid
-
Molecular Weight 679.78
-
Formula C34H41N5O8S
-
Color White to off-white
-
SMILES
O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C)C7=O)N7[C@H]2CC8=CC=CC=C8.CS(=O)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Science
2025 Feb 21;387(6736):892-900. PMID: 39977508 -
Nat Commun
2024 Sep 3;15(1):7654. PMID: 39227578
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
THLE3, Hep3B and HepG2 cells were treated with DMSO or DHE (20, 40, 60 μM) as indicated concentration for 48 h under hypoxia, followed by crystal violet staining assay.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
His-PADI4 proteins were incubated with DMSO or DHE (10, 60 μM) under the indicated temperature before western blotting analysis.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Cell lysates of Hep3B-Flag-PADI4 cells were incubated with DMSO, 50 μM DHE, or 50 μM BBCA at 37 °C for 20 min before western blotting analysis. The samples were derived from the same experiment, but different gels for pan-Cit, another for Flag, Actin were processed in parallel.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Pull-down of His-PADI4 by GST-HIF-1α in the presence of DMSO or DHE as indicated concentration. g An in vitro citrullination assay of GST-HIF-1α was performed in the presence of DMSO or DHE as indicated concentration. The samples were derived from the same experiment, but different gels for R698Cit, His, another for GST were processed in parallel.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Total mRNA in Hep3B cells treated with DMSO or 20 μM, or 40 μM DHE under hypoxic conditions for 24 h were subjected to RNA-sequencing, followed by GO biological processes analysis.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Total mRNA in Hep3B cells treated with DMSO or 20 μM, or 40 μM DHE under hypoxic conditions for 24 h were subjected to RNA-sequencing, followed by GSEA analysis.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Parental Hep3B cells were injected subcutaneously into the flanks of BALB/c nude mice (n = 6 per group). After 12 days, the mice were treated with DMSO or DHE (25 mg/kg or 75 mg/kg) by i.g every 2 days. Tumour volume was determined starting on Day 14 and photographs show xenografts at the end of the experiment.
Dihydroergotamine mesylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 3;15(1):7654. [Abstract]
Parental Hep3B cells were injected subcutaneously into the flanks of BALB/c nude mice (n = 6 per group). After 12 days, the mice were treated with DMSO or DHE (25 mg/kg or 75 mg/kg) by i.g every 2 days. Tumour weight was measured.
-
Free Radic Biol Med
Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]2026 Aug 16:252:493-508. PMID: 42061481 -
Biofactors
GRHL2/SENP1/VDR Signaling Axis: A Key Regulator of SUMOylation and Calcitriol Resistance in SHPT. [Abstract]2026 Mar-Apr;52(2):e70086. PMID: 41760369 -
Biomed Pharmacother
Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods. [Abstract]2025 Aug:189:118246. PMID: 40543162 -
Elife
2020 Dec 7:9:e61405. PMID: 33284104
Solvent & Solubility
DMSO : 50 mg/mL (73.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG400 50% Saline
Solubility: 25 mg/mL (36.78 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (453 KB)
- English - EN (453 KB)
- Français - FR (453 KB)
- Deutsch - DE (453 KB)
- Norwegian - NO (453 KB)
- Español - ES (453 KB)
- Swedish - SV (453 KB)
- Italian - IT (453 KB)
- Korean - KR (453 KB)
- Portuguese - PT (453 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4711 mL | 7.3553 mL | 14.7106 mL | 36.7766 mL |
| 5 mM | 0.2942 mL | 1.4711 mL | 2.9421 mL | 7.3553 mL | |
| 10 mM | 0.1471 mL | 0.7355 mL | 1.4711 mL | 3.6777 mL | |
| 15 mM | 0.0981 mL | 0.4904 mL | 0.9807 mL | 2.4518 mL | |
| 20 mM | 0.0736 mL | 0.3678 mL | 0.7355 mL | 1.8388 mL | |
| 25 mM | 0.0588 mL | 0.2942 mL | 0.5884 mL | 1.4711 mL | |
| 30 mM | 0.0490 mL | 0.2452 mL | 0.4904 mL | 1.2259 mL | |
| 40 mM | 0.0368 mL | 0.1839 mL | 0.3678 mL | 0.9194 mL | |
| 50 mM | 0.0294 mL | 0.1471 mL | 0.2942 mL | 0.7355 mL | |
| 60 mM | 0.0245 mL | 0.1226 mL | 0.2452 mL | 0.6129 mL |
Dihydroergotamine mesylate Related Classifications
HY-B0670A Related Classifications
Powered by Bioz